Prognostic Impact of Adiposity in Hematological Malignancies: A Systematic Review and Meta-analysis.
Adipose
Aml
Body composition
Lymphoma
Multiple myeloma
Vat
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
20
04
2022
revised:
19
05
2022
accepted:
25
05
2022
pubmed:
25
6
2022
medline:
28
9
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
It has been proposed that direct measurement of adiposity has a greater accuracy as a prognostic factor in various malignancies than anthropometric measures such as BMI. We evaluated the association of visceral and subcutaneous adiposity with outcomes in patients with hematological malignancies with a systematic review and meta-analysis. This systematic review included patients with hematological malignancies who had the analysis of overall mortality and progression-free survival according to their adiposity status. We identified 3137 articles, of which we included seven studies. Patients with visceral low visceral adiposity had 2 times greater mortality risk (HR 2.02, P = .0004) and 80% higher risk of death or disease progression (HR 2.98, P = 0.0002), than patients with normal visceral obesity. Patients classified with subcutaneous adipopenia had almost 3 times greater mortality risk. In conclusion, hematological malignancy patients having low adiposity (subcutaneous or visceral) have worse outcomes.
Identifiants
pubmed: 35750574
pii: S2152-2650(22)00169-0
doi: 10.1016/j.clml.2022.05.008
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-734Informations de copyright
Copyright © 2022. Published by Elsevier Inc.